ArticleFrontiers in cellular and infection microbiology2025
Metagenomic next-generation sequencing for cryptococcal meningitis diagnosis: a single-center experience.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.Current opinion in infectious diseases · 2026Review
- Clinical utility of CSF metagenomic next-generation sequencing in suspected CNS infection: performance against a composite reference standard and read-count stratification.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cryptococcal meningitis (CM) is a devastating central nervous system infection with substantial mortality, particularly when diagnosis is delayed. This study aims to evaluate the diagnostic performance of metagenomic next-generation sequencing (mNGS) for CM detection in comparison with conventional tests. Methods: We enrolled 23 consecutive patients with suspected CM at a tertiary center. All patients met a composite reference standard (CRS) based on CSF cryptococcal antigen (CrAg), CSF/sterile-site culture for Cryptococcus, or CNS histopathology; mNGS was excluded from the CRS. Primary outcomes were CRS-based sensitivity (computed only among CRS-positive patients who underwent each assay) and turnaround times (TATs); pairwise agreement metrics (PPA/NPA) between mNGS and conventional assays were estimated in co-tested subsets. Results: mNGS identified Cryptococcus in 18/23 (78.3%) cases and detected viral co-pathogens (EBV/CMV/HIV-1) in 5 patients. CRS-based sensitivities were: CrAg LFA (CSF) 83.3% (5/6), Alcian blue 72.7% (16/22), India ink 50.0% (3/6), and CSF culture 66.7% (8/12). Pairwise agreement favored mNGS against culture and CrAg (e.g., PPA 100% vs culture 8/8] and vs CSF CrAg [5/5]), with limited NPA where denominators were small. Median (IQR) TATs were 0.5 (0.5-0.5) days for CrAg LFA, 1 (0.5-1) day for India ink, 5 (3-8) days for first positive culture, and 2 (1-4) days for mNGS. Conclusion: CSF mNGS complements CrAg, microscopy, and culture by increasing Cryptococcus detection and revealing mixed infections, with particular utility in atypical, pretreated, or complex hosts. Larger studies are warranted to validate clinical utility and define optimal integration with existing workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.